Pharming Group N.V.

PHAR: Is Pharming Group N.V. Halal?

Pharming Group N.V.

NASDAQHealthcareNL

$13.77

+0.84%

Market Cap: 972.5M

Compliance Status

Halal

Screened on Aug 31, 2026 · AAOIFI Standard 21

B

Acceptable

67Score

Is Pharming Group N.V. (PHAR) halal? Halal. Based on AAOIFI screening, Pharming Group N.V. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 67/100 (Grade: B).

Quote this verdict

HalalScreener rates Pharming Group N.V. (PHAR) Halal, 67/100, grade B under AAOIFI Standard 21, screened Aug 31, 2026. Source: https://halalscreener.app/en/stock/PHAR

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

14.2% of 30.0% limit

What this means for you

You can own PHAR

It passes both the business activity and financial ratio screens under AAOIFI Standard 21.

Purification amount is Pro

We have screened PHAR's prohibited income, but the exact share you would need to purify is part of Pro.

About Pharming Group N.V.

Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Aug 31, 2026

Compliance History

  1. Halalnow

    since Aug 2026

  2. Doubtful

    until the change above

  3. Halal

    until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: FY 2025Data source: FMP
Free · No credit card required

Track PHAR and 6,200+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

6,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Pharming Group N.V. (PHAR) halal to invest in?
Based on AAOIFI Standard 21 screening, Pharming Group N.V. (PHAR) is rated Halal with a compliance grade of B (Acceptable). It passes both the business activity screen (no primary involvement in prohibited sectors) and the quantitative financial ratio screen (debt, interest deposits, and prohibited income all below AAOIFI thresholds).
Why did Pharming Group N.V. get a B compliance rating?
Pharming Group N.V. (PHAR) received a grade of B (Acceptable) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 14.2% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.
What could change Pharming Group N.V.'s Shariah verdict?
Pharming Group N.V.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.
How often is Pharming Group N.V. re-screened for Shariah compliance?
Pharming Group N.V. (PHAR) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Aug 31, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.